{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:18:51Z","timestamp":1777781931465,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2007048"],"award-info":[{"award-number":["APP2007048"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union \u2013 Horizon 2020 Research and Innovation Programme"},{"DOI":"10.13039\/501100001030","name":"national heart foundation of australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHMRC Centre of Research Excellence in Medicines Intelligence","award":["1196900"],"award-info":[{"award-number":["1196900"]}]},{"DOI":"10.13039\/501100001773","name":"university of new south wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health and Medical Research Council (NHMRC) \u2013 Leadership Grant","award":["2026765"],"award-info":[{"award-number":["2026765"]}]},{"DOI":"10.13039\/501100004359","name":"vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-01119"],"award-info":[{"award-number":["2022-01119"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","award":["FO2021-0115, FO2022-0327"],"award-info":[{"award-number":["FO2021-0115, FO2022-0327"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Atten Disord"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite cardiovascular conditions being common in adults with ADHD, data on patterns of cardiovascular medicine use in this population are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Using dispensing claims for a 10% random sample of Australians, this population-based study comprised 14,753 adults with ADHD (defined as having \u22652 ADHD medicine dispensings in 2012\u20132020) who were 1:4 sex- and age-matched with 59,012 adults without ADHD (no ADHD dispensings). We estimated the prevalence of cardiovascular medicine use in 2021 among adults with and without ADHD, overall and by medicine type, sex, and age. Using Poisson regression, we calculated age- and sex-adjusted prevalence ratios (PRs) with 95% confidence intervals (CIs) to assess associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall cardiovascular medicine use was more prevalent among adults with ADHD than those without (16.5% vs. 10.0%, aPR\u2009=\u20091.7, 95% CI [1.6, 1.7]), with the highest difference among those aged 18 to 29\u2009years (aPR\u2009=\u20092.8, 95% CI [2.4, 3.1]). We observed increased differences in use of propranolol (3.2% vs. 0.7%), loop diuretics (0.8% vs. 0.4%), potassium-sparing diuretics (0.9% vs. 0.4%), cardiac therapy (0.8% vs. 0.5%), and antithrombotic agents (2.2% vs. 1.4%). Among females, we noted associations of ADHD with specific diuretic subgroups (loop, aPR\u2009=\u20092.8, 95% CI [2.1, 3.7]; potassium-sparing, aPR\u2009=\u20092.5, 95% CI [1.9, 3.3]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We identified an elevated prevalence of cardiovascular medicine use among adults with ADHD, particularly among younger people. We also observed distinct patterns in specific medicine use between sexes, suggesting potential sex-specific effect modification. Our findings underscore the importance of regular monitoring and management of cardiovascular health among people with ADHD across the lifespan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10870547261418763","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:21:31Z","timestamp":1774671691000},"page":"773-783","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Medicine Use Among Adults With ADHD: A Nationwide Study in Australia"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1075-7850","authenticated-orcid":false,"given":"Masako","family":"Araki","sequence":"first","affiliation":[{"name":"UNSW Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helga","family":"Zoega","sequence":"additional","affiliation":[{"name":"University of Iceland, Reykjav\u00edk, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Gillies","sequence":"additional","affiliation":[{"name":"UNSW Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6444-7272","authenticated-orcid":false,"given":"Michael O.","family":"Falster","sequence":"additional","affiliation":[{"name":"UNSW Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Peiris","sequence":"additional","affiliation":[{"name":"UNSW Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"UNSW Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Larsson","sequence":"additional","affiliation":[{"name":"\u00d6rebro University, Sweden"},{"name":"Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-023X","authenticated-orcid":false,"given":"Juliana de Oliveira","family":"Costa","sequence":"additional","affiliation":[{"name":"UNSW Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"crossref","unstructured":"Agnew-Blais J. C. Polanczyk G. V. Danese A. Wertz J. Moffitt T. E. Arseneault L. (2018). Young adult mental health and functional outcomes among individuals with remitted persistent and late-onset ADHD. The British Journal of Psychiatry 213(3) 526\u2013534. https:\/\/doi.org\/10.1192\/bjp.2018.97","DOI":"10.1192\/bjp.2018.97"},{"key":"e_1_3_4_3_1","unstructured":"Australian ADHD Professionals Association. (2022). ADHD stimulant prescribing regulations & authorities in Australia & New Zealand. https:\/\/aadpa.com.au\/adhd-stimulant-prescribing-regulations-in-australia-new-zealand\/"},{"key":"e_1_3_4_4_1","doi-asserted-by":"crossref","unstructured":"Boyce T. G. Ballone N. T. Certa K. M. Becker M. A. (2021). The use of \u03b2\u2011adrenergic receptor antagonists in psychiatry: A review. Journal of the Academy of Consultation-Liaison Psychiatry 62(4) 404\u2013412. https:\/\/doi.org\/10.1016\/j.jaclp.2020.12.009","DOI":"10.1016\/j.jaclp.2020.12.009"},{"key":"e_1_3_4_5_1","doi-asserted-by":"crossref","unstructured":"Bruno C. Havard A. Gillies M. Coghill D. Brett J. Guastella A. Pearson S.-A. Zoega H. (2022). Patterns of attention deficit hyperactivity disorder medicine use in the era of new non-stimulant medicines: A population-based study among Australian children and adults (2013\u20132020). Australian & New Zealand Journal of Psychiatry 57(5) 675\u2013685. https:\/\/doi.org\/10.1177\/00048674221114782","DOI":"10.1177\/00048674221114782"},{"key":"e_1_3_4_6_1","doi-asserted-by":"crossref","unstructured":"Butt A. K. Patel J. Shirwany H. Mirza Q. Hoover J. Khouzam R. N. (2022). Beneficial extracardiac effects of cardiovascular medications. Current Cardiology Reviews 18(2) e151021197270. https:\/\/doi.org\/10.2174\/1573403x17666211015145132","DOI":"10.2174\/1573403X17666211015145132"},{"key":"e_1_3_4_7_1","doi-asserted-by":"crossref","unstructured":"Choi W.-S. Woo Y. S. Wang S.-M. Lim H. K. Bahk W.-M. (2022). The prevalence of psychiatric comorbidities in adult ADHD compared with non-ADHD populations: A systematic literature review. PLoS ONE 17(11) e0277175. https:\/\/doi.org\/10.1371\/journal.pone.0277175","DOI":"10.1371\/journal.pone.0277175"},{"key":"e_1_3_4_8_1","doi-asserted-by":"crossref","unstructured":"Di Lorenzo R. Balducci J. Cutino A. Latella E. Venturi G. Rovesti S. Filippini T. Ferri P. (2023). ADHD follow-up in adulthood among subjects treated for the disorder in a child and adolescent mental health service from 1995 to 2015. Medicina 59(2) 338. https:\/\/doi.org\/10.3390\/medicina59020338","DOI":"10.3390\/medicina59020338"},{"key":"e_1_3_4_9_1","doi-asserted-by":"crossref","unstructured":"Du Rietz E. Brikell I. Butwicka A. Leone M. Chang Z. Cortese S. D\u2019Onofrio B. M. Hartman C. A. Lichtenstein P. Faraone S. V. Kuja-Halkola R. Larsson H. (2021). Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: A genetically informed register study. The Lancet Psychiatry 8(9) 774\u2013783. https:\/\/doi.org\/10.1016\/S2215-0366(21)00171-1","DOI":"10.1016\/S2215-0366(21)00171-1"},{"key":"e_1_3_4_10_1","doi-asserted-by":"crossref","unstructured":"Ganson K. T. Hallward L. Cunningham M. L. Murray S. B. Nagata J. M. (2023). Use of legal appearance- and performance-enhancing drugs and substances: Findings from the Canadian study of adolescent health behaviors. Substance Use & Misuse 58(2) 289\u2013297. https:\/\/doi.org\/10.1080\/10826084.2022.2161318","DOI":"10.1080\/10826084.2022.2161318"},{"key":"e_1_3_4_11_1","doi-asserted-by":"crossref","unstructured":"Garcia-Argibay M. du Rietz E. Lu Y. Martin J. Haan E. Lehto K. Bergen S. E. Lichtenstein P. Larsson H. Brikell I. (2022). The role of ADHD genetic risk in mid-to-late life somatic health conditions. Translational Psychiatry 12(1) 152. https:\/\/doi.org\/10.1038\/s41398-022-01919-9","DOI":"10.1038\/s41398-022-01933-x"},{"key":"e_1_3_4_12_1","doi-asserted-by":"crossref","unstructured":"Langan S. M. Schmidt S. A. Wing K. Ehrenstein V. Nicholls S. G. Filion K. B. Klungel O. Petersen I. Sorensen H. T. Dixon W. G. Guttmann A. Harron K. Hemkens L. G. Moher D. Schneeweiss S. Smeeth L. Sturkenboom M. von Elm E. Wang S. V. Benchimol E. I. (2018). The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 363 k3532. https:\/\/doi.org\/10.1136\/bmj.k3532","DOI":"10.1136\/bmj.k3532"},{"key":"e_1_3_4_13_1","doi-asserted-by":"crossref","unstructured":"Li L. Chang Z. Sun J. Garcia-Argibay M. Du Rietz E. Dobrosavljevic M. Brikell I. Jernberg T. Solmi M. Cortese S. Larsson H. (2022). Attention-deficit\/hyperactivity disorder as a risk factor for cardiovascular diseases: A nationwide population-based cohort study. World Psychiatry 21(3) 452\u2013459. https:\/\/doi.org\/10.1002\/wps.21020","DOI":"10.1002\/wps.21020"},{"key":"e_1_3_4_14_1","doi-asserted-by":"crossref","unstructured":"Li L. Yao H. Zhang L. Garcia-Argibay M. Du Rietz E. Brikell I. Solmi M. Cortese S. Ramos-Quiroga J. A. Ribas\u00e9s M. Chang Z. Larsson H. (2023). Attention-deficit\/hyperactivity disorder is associated with increased risk of cardiovascular diseases: A systematic review and meta-analysis. JCPP Advances 3(3) e12158. https:\/\/doi.org\/10.1002\/jcv2.12158","DOI":"10.1002\/jcv2.12158"},{"key":"e_1_3_4_15_1","doi-asserted-by":"crossref","unstructured":"Lin H.-W. Phan K. Lin S.-J. (2006). Trends in off-label \u03b2-blocker use: A secondary data analysis. Clinical Therapeutics 28(10) 1736\u20131746. https:\/\/doi.org\/10.1016\/j.clinthera.2006.10.015","DOI":"10.1016\/j.clinthera.2006.10.015"},{"key":"e_1_3_4_16_1","doi-asserted-by":"crossref","unstructured":"Mellish L. Karanges E. A. Litchfield M. J. Schaffer A. L. Blanch B. Daniels B. J. Segrave A. Pearson S.-A. (2015). The Australian Pharmaceutical Benefits Scheme data collection: A practical guide for researchers. BMC Research Notes 8(1) 634. https:\/\/doi.org\/10.1186\/s13104-015-1616-8","DOI":"10.1186\/s13104-015-1616-8"},{"key":"e_1_3_4_17_1","unstructured":"National Heart Foundation of Australia. (2016). Guideline for the diagnosis and management of hypertension in adults. https:\/\/assets.contentstack.io\/v3\/assets\/blt8a393bb3b76c0ede\/bltbf3d36e10b48f01f\/65b0963ea933e532ae0286de\/01_Hypertension-guideline-2016_WEB.pdf"},{"key":"e_1_3_4_18_1","doi-asserted-by":"crossref","unstructured":"NHFA CSANZ Heart Failure Guidelines Working Group Atherton J. J. Sindone A. De Pasquale C. G. Driscoll A. MacDonald P. S. Hopper I. Kistler P. M. Briffa T. Wong J. Abhayaratna W. Thomas L. Audehm R. Newton P. O'Loughlin J. Branagan M. Connell C. (2018). National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the prevention detection and management of heart failure in Australia 2018. Heart Lung and Circulation 27(10) 1123\u20131208. https:\/\/doi.org\/10.1016\/j.hlc.2018.06.1042","DOI":"10.1016\/j.hlc.2018.06.1042"},{"key":"e_1_3_4_19_1","doi-asserted-by":"crossref","unstructured":"O\u2019Dea J. Cinelli R. L. (2016). Use of drugs to change appearance in girls and female adolescents. In Hall M. Grogan S. Gough B. (Eds.) Chemically modified bodies: The use of diverse substances for appearance enhancement (pp. 51\u201376). Palgrave Macmillan UK. https:\/\/doi.org\/10.1057\/978-1-137-53535-1_4","DOI":"10.1057\/978-1-137-53535-1_4"},{"key":"e_1_3_4_20_1","doi-asserted-by":"crossref","unstructured":"Okoth K. Chandan J. S. Marshall T. Thangaratinam S. Thomas G. N. Nirantharakumar K. Adderley N. J. (2020). Association between the reproductive health of young women and cardiovascular disease in later life: Umbrella review. BMJ 371 m3502. https:\/\/doi.org\/10.1136\/bmj.m3502","DOI":"10.1136\/bmj.m3502"},{"key":"e_1_3_4_21_1","doi-asserted-by":"crossref","unstructured":"Penninx B. W. J. H. Lange S. M. M. (2018). Metabolic syndrome in psychiatric patients: Overview mechanisms and implications. Dialogues in Clinical Neuroscience 20(1) 63\u201373. https:\/\/doi.org\/10.31887\/DCNS.2018.20.1\/bpenninx","DOI":"10.31887\/DCNS.2018.20.1\/bpenninx"},{"key":"e_1_3_4_22_1","doi-asserted-by":"crossref","unstructured":"Poluzzi E. Korhonen M. J. (2016). Drug utilization research in the area of cardiovascular medicines. In Elseviers M. Wettermark B. Almarsd\u00f3ttir A. B. Andersen M. Benko R. Bennie M. Eriksson I. Godman B. Krska J. Poluzzi E. Taxis K. Vlahovi\u0107-Pal\u010devski V. Stichele R. V. (Eds.) Drug utilization research (pp. 284\u2013293). Wiley. https:\/\/doi.org\/10.1002\/9781118949740.ch27","DOI":"10.1002\/9781118949740.ch27"},{"key":"e_1_3_4_23_1","doi-asserted-by":"crossref","unstructured":"Posner J. Polanczyk G. V. Sonuga-Barke E. (2020). Attention-deficit hyperactivity disorder. The Lancet 395(10222) 450\u2013462. https:\/\/doi.org\/10.1016\/S0140-6736(19)33004-1","DOI":"10.1016\/S0140-6736(19)33004-1"},{"key":"e_1_3_4_24_1","doi-asserted-by":"crossref","unstructured":"Pratt N. L. Kerr M. Barratt J. D. Kemp-Casey A. Kalisch Ellett L. M. Ramsay E. Roughead E. E. (2018). The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System. BMJ Open 8(4) e021122. https:\/\/doi.org\/10.1136\/bmjopen-2017-021122","DOI":"10.1136\/bmjopen-2017-021122"},{"key":"e_1_3_4_25_1","doi-asserted-by":"crossref","unstructured":"Simon V. Czobor P. B\u00e1lint S. M\u00e9sz\u00e1ros \u00c1. Bitter I. (2009). Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. The British Journal of Psychiatry 194(3) 204\u2013211. https:\/\/doi.org\/10.1192\/bjp.bp.107.048827","DOI":"10.1192\/bjp.bp.107.048827"},{"key":"e_1_3_4_26_1","doi-asserted-by":"crossref","unstructured":"Thomas R. Sanders S. Doust J. Beller E. Glasziou P. (2015). Prevalence of attention-deficit\/hyperactivity disorder: A systematic review and meta-analysis. Pediatrics 135(4) e994\u2013e1001. https:\/\/doi.org\/10.1542\/peds.2014-3482","DOI":"10.1542\/peds.2014-3482"},{"key":"e_1_3_4_27_1","doi-asserted-by":"crossref","unstructured":"Treur J. L. Demontis D. Smith G. D. Sallis H. Richardson T. G. Wiers R. W. B\u00f8rglum A. D. Verweij K. J. H. Munaf\u00f2 M. R. (2021). Investigating causality between liability to ADHD and substance use and liability to substance use and ADHD risk using Mendelian randomization. Addiction Biology 26(1) e12849. https:\/\/doi.org\/10.1111\/adb.12849","DOI":"10.1111\/adb.12849"},{"key":"e_1_3_4_28_1","doi-asserted-by":"crossref","unstructured":"Vogel B. Acevedo M. Appelman Y. Bairey Merz C. N. Chieffo A. Figtree G. A. Guerrero M. Kunadian V. Lam C. S. P. Maas A. H. E. M. Mihailidou A. S. Olszanecka A. Poole J. E. Saldarriaga C. Saw J. Z\u00fchlke L. Mehran R. (2021). The Lancet women and cardiovascular disease Commission: Reducing the global burden by 2030. The Lancet 397(10292) 2385\u20132438. https:\/\/doi.org\/10.1016\/S0140-6736(21)00684-X","DOI":"10.1016\/S0140-6736(21)00684-X"},{"key":"e_1_3_4_29_1","doi-asserted-by":"crossref","unstructured":"Young S. Adamo N. \u00c1sgeirsd\u00f3ttir B. B. Branney P. Beckett M. Colley W. Cubbin S. Deeley Q. Farrag E. Gudjonsson G. Hill P. Hollingdale J. Kilic O. Lloyd T. Mason P. Paliokosta E. Perecherla S. Sedgwick J. Skirrow C. . . . Woodhouse E. (2020). Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit\/hyperactivity disorder in girls and women. BMC Psychiatry 20(1) 404. https:\/\/doi.org\/10.1186\/s12888-020-02707-9","DOI":"10.1186\/s12888-020-02707-9"},{"key":"e_1_3_4_30_1","doi-asserted-by":"crossref","unstructured":"Zhang L. Li L. Andell P. Garcia-Argibay M. Quinn P. D. D\u2019Onofrio B. M. Brikell I. Kuja-Halkola R. Lichtenstein P. Johnell K. Larsson H. Chang Z. (2024). Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry 81(2) 178\u2013187. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4294","DOI":"10.1001\/jamapsychiatry.2023.4294"},{"key":"e_1_3_4_31_1","doi-asserted-by":"crossref","unstructured":"Zhang L. Reif A. Du Rietz E. Lagerberg T. Butwicka A. D\u2019Onofrio B. M. Johnell K. Pedersen N. L. Larsson H. Chang Z. (2021). Comedication and polypharmacy with ADHD medications in adults: A Swedish nationwide study. Journal of Attention Disorders 25(11) 1519\u20131528. https:\/\/doi.org\/10.1177\/1087054720923725","DOI":"10.1177\/1087054720923725"},{"key":"e_1_3_4_32_1","doi-asserted-by":"crossref","unstructured":"Zhang L. Yao H. Li L. Du Rietz E. Andell P. Garcia-Argibay M. D\u2019Onofrio B. M. Cortese S. Larsson H. Chang Z. (2022). Risk of cardiovascular diseases associated with medications used in attention-deficit\/hyperactivity disorder: A systematic review and meta-analysis. JAMA Network Open 5(11) e2243597. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.43597","DOI":"10.1001\/jamanetworkopen.2022.43597"}],"container-title":["Journal of Attention Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10870547261418763","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10870547261418763","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10870547261418763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:30:52Z","timestamp":1777491052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10870547261418763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10870547261418763"],"URL":"https:\/\/doi.org\/10.1177\/10870547261418763","relation":{},"ISSN":["1087-0547","1557-1246"],"issn-type":[{"value":"1087-0547","type":"print"},{"value":"1557-1246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}